Sebastien Calbo

Rouen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

Journal: The Journal of investigative dermatology

Published: May 18, 2026

Production of Functional Trastuzumab in Phaeodactylum tricornutum: Advancing Microalgae as Next-Generation Sustainable Antibody Biofactories.

Production of Functional Trastuzumab in Phaeodactylum tricornutum: Advancing Microalgae as Next-Generation Sustainable Antibody Biofactories.

Journal: Plant biotechnology journal

Published: December 24, 2025

Tocilizumab for severe and refractory mucous membrane pemphigoid.

Tocilizumab for severe and refractory mucous membrane pemphigoid.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 04, 2025

Prevalence and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus.

Prevalence and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus.

Journal: The British journal of dermatology

Published: November 06, 2025

Persistence of anti-Desmoglein 3 Antibodies in Patients with Pemphigus Vulgaris in Clinical Remission is Associated with Restricted Isotype Diversity and Desmoglein 3 Ectodomain Recognition.

Persistence of anti-Desmoglein 3 Antibodies in Patients with Pemphigus Vulgaris in Clinical Remission is Associated with Restricted Isotype Diversity and Desmoglein 3 Ectodomain Recognition.

Journal: The British journal of dermatology

Published: October 23, 2025

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

Journal: JAMA dermatology

Published: March 05, 2025

Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.

Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.

Journal: The British journal of dermatology

Published: March 07, 2024

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Journal: JAMA dermatology

Published: January 24, 2024

The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.

The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.

Journal: The British journal of dermatology

Published: May 16, 2023

Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants.

Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants.

Journal: Marine drugs

Published: September 25, 2022

Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus.

Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus.

Journal: JAMA dermatology

Published: June 22, 2022

IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.

IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.

Journal: Biomedicines

Published: May 25, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026